Chemcon Speciality Chemicals Ltd
CHEMCONChemcon Speciality Chemicals Ltd's earnings have outrun its stock. EPS grew −3.4% in a year against a −24.4% price move.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is in a downtrend (32 weeks in) while the P/E sits at the 39th percentile of its own 6-year range. Underneath, the last four quarters read improving — profit +61.3% year on year, and 142% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Chemcon Speciality Chemicals Ltd trades at ₹176, in a downtrend and 32 weeks into that stage. That is −6.3% against its own 200-day average. It sits at 31% of a 52-week range of ₹134 to ₹270. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is in a downtrend — week 32 of stage 4. At ₹176 it trades −6.3% versus its 200-day average and sits at 31% of its 52-week range (₹134–₹270).
Against the market, two honest reads. Cumulative: over the last 5.8 years the stock moved −70% while the NIFTY 500 moved +143% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-07-10) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Chemcon Speciality Chemicals Ltd trades at 27.2× P/E, mid-range by its own standards (39th percentile). Its long-run median P/E is 28.7×, measured across 5.8 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 27.2× is mid-range by its own standards (39th percentile), against a long-run median of 28.7× measured over 5.8 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −3.4% against a −24.4% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −18.9%/yr price move, ~−16.4%/yr came from earnings growth and ~−2.5 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Chemcon Speciality Chemicals Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 8 quarters ago at −60.9% and has held its recovery at +61.3% (single-quarter readings), ROCE slipping at 6.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +15.9% | −7.5% | −0.2% | +9.5% |
| Profit | +0.0% | −24.2% | −15.6% | +23.1% |
| EPS | −3.4% | −24.6% | −16.0% | +4.6% |
| Share price | −24.4% | −13.2% | −18.9% | — |
4-Factor Sector Score
40.4/100 — rank 20 of 27 in Speciality Chemicals · 77% evidence confidence
Chemcon Speciality Chemicals Ltd scores 40.4 out of 100 against the 27 companies it is compared with in Speciality Chemicals, ranking 20. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 16.1 + 8.8 + 11.5 + 4 = 40.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Chemcon Speciality Chemicals Ltd reported ₹75.4 Cr of revenue in the Mar 26 quarter, +37.4% year on year. That is the 4th straight quarter of year-on-year growth. Over 10 years it has compounded at 9.5% a year. The last full year, FY26, came in at ₹240 Cr. The last four reported quarters add to ₹240 Cr.
FY26 revenue came in at ₹240 Cr (+15.9% on the year), capping 10 years at 9.5% compound. The latest quarter (Mar 26) printed ₹75.4 Cr, +37.4% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +15.6% growth against the decade's 9.5% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +15.7% over the last 4 quarters against −5.2%/yr over the last 8 — accelerating; TTM profit −3.5% vs +10.9%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Chemcon Speciality Chemicals Ltd's operating margin is 11.8% in the Mar 26 quarter, +1.2 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0% to 33.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 11.8%, +1.2 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0%–33.0%.
Why the margin moved: operating margin went +1.2 pp year on year while gross margin went −7.6 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Chemcon Speciality Chemicals Ltd earned ₹6.4 Cr of net profit in the Mar 26 quarter, +61.3% year on year. Full-year FY26 profit was ₹24.0 Cr. The 10-year compound rate is 23.1%. That is 8.4% of the quarter's revenue. The same quarter a year earlier earned ₹4.0 Cr.
Mar 26 profit was ₹6.4 Cr, +61.3% year on year. On the full year, FY26 printed ₹24.0 Cr (+0.0%), and the 10-year compound rate is 23.1%.
Why profit moved: revenue contributed +37.4% and the margin +1.2 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +7.2% vs revenue +15.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 142% of Chemcon Speciality Chemicals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹42.0 Cr of operating cash against ₹24.0 Cr of profit. After ₹39.0 Cr of capital spending, ₹3.0 Cr was left as free cash.
FY26: operating cash of ₹42.0 Cr against reported profit of ₹24.0 Cr, leaving free cash of ₹3.0 Cr after ₹39.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 142% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 142%: the cash cycle tightened 38 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 2.8× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Chemcon Speciality Chemicals Ltd's cash conversion cycle runs 212 days in FY26, down from 250 days in FY21. Capital spending ran ₹94.0 Cr over the last 3 years. At FY26 sales of ₹240 Cr each day of that cycle holds about ₹0.7 Cr, so roughly ₹139 Cr sits inside the business at any moment.
FY26: debtors at 97 days, inventory at 158 days — roughly 5.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 212 days, tighter than FY21's 250.
The full loop: cash goes out to suppliers and production on day 0; stock waits 158 days to sell; customers pay about 97 days after that; and suppliers themselves are paid at 42 days — netting out to the 212-day cycle.
In money terms: at FY26 sales of ₹240 Cr, each day of the cycle holds about ₹0.7 Cr — so the 212-day loop keeps roughly ₹139 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹94.0 Cr over the last 3 fiscal years against ₹33.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹21.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Chemcon Speciality Chemicals Ltd earns a ROCE of 6% in FY26. That is up from a trough of 6% in FY24. Return on invested capital clears the cost of that capital by −8.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 10.0% net margin on 0.42× asset turns.
FY26 ROCE is 6%, recovered from a FY24 trough of 6% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 10.0% net margin × 0.42× asset turns × 1.17× balance-sheet leverage ≈ 4.9% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 3.7% − 12.0% = a −8.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Chemcon Speciality Chemicals Ltd carries total debt of ₹53.0 Cr against shareholder equity of ₹483 Cr as of Mar 26, a debt-to-equity of 0.11 — effectively unlevered. On the annual view that ratio went from 0.09 in FY22 to 0.11 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹53.0 Cr against shareholder equity of ₹483 Cr — a debt-to-equity of 0.11. On the annual view, debt-to-equity went from 0.09 (FY22) to 0.11 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Chemcon Speciality Chemicals Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved +0.0 points over the same window, to 74.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −0.3 points over 8 quarters to 0.0%; Promoters: +0.0 points over 8 quarters to 74.5%; Foreign institutions: +0.0 points over 8 quarters to 0.3%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Chemcon Speciality Chemicals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Sunshield Chemicals Ltd530845 | 70.0/100Favorable setup72% evidence | TURNING | 28.4/35 Revenue 20.5% · PAT 100% · OPM change 5 pp 83% evidence | 16.3/25 ROCE 19.9% · OPM 15% 76% evidence | 11.2/20 P/E 35.1× · PEG — 50% evidence | 14.1/20 RS sector 2.3% · RS bench 22.4% · 1Y 59.8%11 of 11 weeks ahead 70% evidence |
| Exact sum: 28.4 + 16.3 + 11.2 + 14.1 = 70 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Privi Speciality Chemicals LtdPRIVISCL | 64.2/100Mixed-positive evidence75% evidence | LEADER | 24.9/35 Revenue 21.6% · PAT 62.1% · OPM change -1 pp 95% evidence | 17.8/25 ROCE 22.3% · OPM 23% 76% evidence | 9.3/20 P/E 40.4× · PEG — 15% evidence | 12.2/20 RS sector 2.6% · RS bench 19.1% · 1Y 45.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 17.8 + 9.3 + 12.2 = 64.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Pidilite Industries LtdPIDILITIND | 63.6/100Mixed-positive evidence90% evidence | TURNING | 21.8/35 Revenue 11.1% · PAT 17.9% · OPM change 3 pp 88% evidence | 19.6/25 ROCE 31% · OPM 23% 100% evidence | 7.6/20 P/E 66.6× · PEG 3.73 100% evidence | 14.6/20 RS sector 5.2% · RS bench 7.2% · 1Y 11.5%6 of 10 weeks ahead 70% evidence |
| Exact sum: 21.8 + 19.6 + 7.6 + 14.6 = 63.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Vikram Thermo (India) Ltd530477 | 63.1/100Mixed-positive evidence63% evidence | TURNING | 23.1/35 Revenue 7% · PAT 100% · OPM change 7.1 pp 83% evidence | 19.2/25 ROCE 36.4% · OPM 31.7% 76% evidence | 8.9/20 P/E 20× · PEG — 50% evidence | 11.9/20 RS sector — · RS bench 40.3% · 1Y —4 of 4 weeks ahead 25% evidence |
| Exact sum: 23.1 + 19.2 + 8.9 + 11.9 = 63.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 5Yasho Industries LtdYASHO | 62.6/100Mixed-positive evidence87% evidence | TURNING | 29.3/35 Revenue 34.1% · PAT 100% · OPM change 7 pp 100% evidence | 8.7/25 ROCE 8.9% · OPM 24% 100% evidence | 12.1/20 P/E 80.7× · PEG 1.15 65% evidence | 12.5/20 RS sector -2.4% · RS bench 109.3% · 1Y 97.1%11 of 11 weeks ahead 70% evidence |
| Exact sum: 29.3 + 8.7 + 12.1 + 12.5 = 62.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Tatva Chintan Pharma Chem LtdTATVA | 61.4/100Mixed-positive evidence93% evidence | BREAKING OUT | 30.7/35 Revenue 41.1% · PAT 100% · OPM change 4 pp 100% evidence | 6.6/25 ROCE 7.1% · OPM 19% 100% evidence | 4.8/20 P/E 79.8× · PEG 5.63 65% evidence | 19.3/20 RS sector 21.3% · RS bench 40.9% · 1Y 56.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 30.7 + 6.6 + 4.8 + 19.3 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Panama Petrochem LtdPANAMAPET | 57.5/100Mixed-positive evidence90% evidence | TURNING | 17.5/35 Revenue 9.7% · PAT 14.5% · OPM change 2 pp 88% evidence | 13.3/25 ROCE 19.2% · OPM 11% 100% evidence | 15.8/20 P/E 12.9× · PEG 0.55 100% evidence | 10.9/20 RS sector -5.8% · RS bench 42.3% · 1Y 31.6%10 of 11 weeks ahead 70% evidence |
| Exact sum: 17.5 + 13.3 + 15.8 + 10.9 = 57.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Kronox Lab Sciences LtdKRONOX | 56.7/100Mixed-positive evidence61% evidence | 13.6/35 Revenue 1% · PAT 8.2% · OPM change 6.8 pp 83% evidence | 21.2/25 ROCE 36% · OPM 36.4% 95% evidence | 11.1/20 P/E 20.3× · PEG — 15% evidence | 10.8/20 RS sector — · RS bench 5.4% · 1Y — 25% evidence | |
| Exact sum: 13.6 + 21.2 + 11.1 + 10.8 = 56.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Alkyl Amines Chemicals LtdALKYLAMINE | 56.5/100Mixed-positive evidence73% evidence | TURNING | 20.5/35 Revenue 17.4% · PAT 100% · OPM change -0.1 pp 71% evidence | 18.9/25 ROCE 41.3% · OPM 14.5% 95% evidence | 9.3/20 P/E 48.2× · PEG — 50% evidence | 7.8/20 RS sector -14.6% · RS bench 3% · 1Y -18.7%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.5 + 18.9 + 9.3 + 7.8 = 56.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Aether Industries LtdAETHER | 55.9/100Mixed-positive evidence100% evidence | BREAKING OUT | 24.5/35 Revenue 34.4% · PAT 34.3% · OPM change -1 pp 100% evidence | 10.6/25 ROCE 11.9% · OPM 31% 100% evidence | 4.3/20 P/E 85.2× · PEG 8.9 100% evidence | 16.5/20 RS sector 30.6% · RS bench 51.5% · 1Y 97%10 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 10.6 + 4.3 + 16.5 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Aarti Industries LtdAARTIIND | 53.7/100Mixed-positive evidence100% evidence | FADING | 27.9/35 Revenue 27% · PAT 100% · OPM change 3 pp 100% evidence | 8.8/25 ROCE 6.8% · OPM 16% 100% evidence | 6.9/20 P/E 34× · PEG 2.05 100% evidence | 10.1/20 RS sector -0.7% · RS bench 15.3% · 1Y 13.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 27.9 + 8.8 + 6.9 + 10.1 = 53.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Vinati Organics LtdVINATIORGA | 50.0/100Mixed-positive evidence76% evidence | ASLEEP | 12.2/35 Revenue 5.1% · PAT 5.7% · OPM change -5 pp 95% evidence | 17.4/25 ROCE 19.8% · OPM 24% 76% evidence | 13.3/20 P/E 30.2× · PEG — 50% evidence | 7.1/20 RS sector -4.1% · RS bench -14% · 1Y -30.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.2 + 17.4 + 13.3 + 7.1 = 50 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 13DMCC Speciality Chemicals LtdDMCC | 49.4/100Mixed-negative evidence76% evidence | FADING | 20.4/35 Revenue 34.8% · PAT 27% · OPM change -2.1 pp 83% evidence | 11.4/25 ROCE 15.3% · OPM 10% 95% evidence | 10.5/20 P/E 25.8× · PEG — 15% evidence | 7.1/20 RS sector -11.1% · RS bench 2.9% · 1Y -9.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 11.4 + 10.5 + 7.1 = 49.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Fineotex Chemical LtdFCL | 47.6/100Mixed-negative evidence94% evidence | TURNING | 18.7/35 Revenue 91.5% · PAT 41% · OPM change -2 pp 100% evidence | 13.0/25 ROCE 18.3% · OPM 16% 100% evidence | 3.3/20 P/E 37.4× · PEG 4.19 100% evidence | 12.6/20 RS sector -2.3% · RS bench 42% · 1Y 45.8%11 of 11 weeks ahead 70% evidence |
| Exact sum: 18.7 + 13 + 3.3 + 12.6 = 47.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Grauer & Weil (India) LtdGRAUWEIL | 46.9/100Mixed-negative evidence96% evidence | TURNING | 15.5/35 Revenue 4.9% · PAT 4.4% · OPM change 8 pp 88% evidence | 16.8/25 ROCE 21.4% · OPM 17% 100% evidence | 7.7/20 P/E 21.2× · PEG 4.01 100% evidence | 6.9/20 RS sector -15% · RS bench -1.6% · 1Y -24.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 16.8 + 7.7 + 6.9 = 46.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Platinum Industries LtdPLATIND | 46.8/100Mixed-negative evidence70% evidence | ASLEEP | 16.7/35 Revenue 14.5% · PAT 0% · OPM change 4 pp 83% evidence | 12.7/25 ROCE 15.7% · OPM 12% 95% evidence | 10.8/20 P/E 23.7× · PEG — 15% evidence | 6.6/20 RS sector -10.6% · RS bench -9% · 1Y -23.9%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.7 + 12.7 + 10.8 + 6.6 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Neogen Chemicals LtdNEOGEN | 44.0/100Mixed-negative evidence90% evidence | LEADER | 15.3/35 Revenue 18.1% · PAT 6.1% · OPM change 2 pp 100% evidence | 6.9/25 ROCE 6.5% · OPM 19% 100% evidence | 5.1/20 P/E 156× · PEG — 50% evidence | 16.7/20 RS sector 15.8% · RS bench 33.3% · 1Y 28.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 15.3 + 6.9 + 5.1 + 16.7 = 44 · Decision use: Price leads the evidence: RS versus the benchmark is 33.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18Vishnu Chemicals LtdVISHNU | 43.5/100Mixed-negative evidence100% evidence | FADING | 15.5/35 Revenue 16.5% · PAT 17.2% · OPM change -1 pp 100% evidence | 11.8/25 ROCE 16.3% · OPM 15% 100% evidence | 6.2/20 P/E 27.6× · PEG 2.82 100% evidence | 10.0/20 RS sector -2.3% · RS bench 13.3% · 1Y 23.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 11.8 + 6.2 + 10 = 43.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Anupam Rasayan India LtdANURAS | 41.5/100Mixed-negative evidence78% evidence | ASLEEP | 20.6/35 Revenue 64.5% · PAT 38.8% · OPM change -7 pp 83% evidence | 10.3/25 ROCE 7.4% · OPM 22% 76% evidence | 8.0/20 P/E 80.8× · PEG — 50% evidence | 2.6/20 RS sector -17.4% · RS bench -3.6% · 1Y 5.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 10.3 + 8 + 2.6 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Chemcon Speciality Chemicals Ltdthis pageCHEMCON | 40.4/100Mixed-negative evidence77% evidence | TURNING | 16.1/35 Revenue 15.7% · PAT -3.5% · OPM change 1.2 pp 83% evidence | 8.8/25 ROCE 6.4% · OPM 11.8% 95% evidence | 11.5/20 P/E 27.2× · PEG — 50% evidence | 4.0/20 RS sector -21.7% · RS bench -12% · 1Y -17.1%9 of 10 weeks ahead 70% evidence |
| Exact sum: 16.1 + 8.8 + 11.5 + 4 = 40.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Galaxy Surfactants LtdGALAXYSURF | 40.1/100Mixed-negative evidence90% evidence | TURNING | 12.0/35 Revenue 24.2% · PAT -13.1% · OPM change -2 pp 88% evidence | 12.9/25 ROCE 13.5% · OPM 9% 100% evidence | 8.9/20 P/E 24.8× · PEG 4.39 100% evidence | 6.3/20 RS sector -12.1% · RS bench -4.1% · 1Y -25.1%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12 + 12.9 + 8.9 + 6.3 = 40.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Amines & Plasticizers LtdAMNPLST | 40.0/100Mixed-negative evidence77% evidence | TURNING | 9.4/35 Revenue -13.8% · PAT -14.3% · OPM change 2 pp 83% evidence | 15.2/25 ROCE 16.7% · OPM 15% 95% evidence | 8.5/20 P/E 29.9× · PEG — 50% evidence | 6.9/20 RS sector -19.4% · RS bench 3.8% · 1Y -12.3%10 of 10 weeks ahead 70% evidence |
| Exact sum: 9.4 + 15.2 + 8.5 + 6.9 = 40 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Transpek Industry LtdTRANSPEK | 38.4/100Mixed-negative evidence77% evidence | TURNING | 8.1/35 Revenue -4.4% · PAT -6.3% · OPM change -7.5 pp 83% evidence | 9.1/25 ROCE 8.3% · OPM 12% 95% evidence | 13.8/20 P/E 16.2× · PEG — 50% evidence | 7.4/20 RS sector -19.7% · RS bench 8% · 1Y -19.4%3 of 10 weeks ahead 70% evidence |
| Exact sum: 8.1 + 9.1 + 13.8 + 7.4 = 38.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 24Paushak LtdPAUSHAKLTD | 36.2/100Mixed-negative evidence81% evidence | TURNING | 11.5/35 Revenue 15.4% · PAT -15.7% · OPM change -1 pp 95% evidence | 9.9/25 ROCE 8.3% · OPM 31% 95% evidence | 8.3/20 P/E 36.6× · PEG — 50% evidence | 6.5/20 RS sector -27.5% · RS bench 7.3% · 1Y -3.2%6 of 11 weeks ahead 70% evidence |
| Exact sum: 11.5 + 9.9 + 8.3 + 6.5 = 36.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Clean Science & Technology LtdCLEAN | 34.1/100Adverse evidence94% evidence | ASLEEP | 4.4/35 Revenue -0.4% · PAT -13.8% · OPM change -5 pp 100% evidence | 17.6/25 ROCE 20.6% · OPM 36% 100% evidence | 8.6/20 P/E 33.5× · PEG 6.24 100% evidence | 3.5/20 RS sector -24.4% · RS bench -18% · 1Y -40.9%2 of 10 weeks ahead 70% evidence |
| Exact sum: 4.4 + 17.6 + 8.6 + 3.5 = 34.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Thirumalai Chemicals LtdTIRUMALCHM | 24.8/100Thin evidence · provisional59% evidence | ASLEEP | 9.1/35 Revenue -15.4% · PAT -80% · OPM change -1.4 pp 62% evidence | 0.9/25 ROCE -3.1% · OPM 1.4% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.8/20 RS sector -15.9% · RS bench -22.9% · 1Y -40.9%1 of 10 weeks ahead 70% evidence |
| Exact sum: 9.1 + 0.9 + 10 + 4.8 = 24.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Amal LtdAMAL | 50.0/100Thin evidence · provisional50% evidence | 19.8/35 Revenue 72.5% · PAT 19.1% · OPM change -31.6 pp 53% evidence | 15.1/25 ROCE 36.3% · OPM 12.9% 57% evidence | 10.9/20 P/E 23× · PEG — 15% evidence | 4.2/20 RS sector -18.2% · RS bench -26.3% · 1Y -51.4%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 19.8 + 15.1 + 10.9 + 4.2 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Chemcon Speciality Chemicals Ltd's share price today?
Chemcon Speciality Chemicals Ltd trades at ₹176, −24.4% over the past year. The company is valued at ₹643 Cr. The stock sits at 31% of its 52-week range of ₹134–₹270, −6.3% versus its 200-day average. On the tape, the price is in a downtrend, 32 weeks in. — as of 31 July 2026.
What were Chemcon Speciality Chemicals Ltd's latest quarterly results?
Chemcon Speciality Chemicals Ltd reported revenue of ₹75.4 Cr and net profit of ₹6.4 Cr for the Mar 26 quarter. Revenue rose 37.4% and profit rose 61.3% year on year. Earnings per share were ₹1.74. The operating margin was 11.8%, 1.2 pp higher than a year earlier. — as of 31 July 2026.
What is Chemcon Speciality Chemicals Ltd's revenue?
Chemcon Speciality Chemicals Ltd reported revenue of ₹75.4 Cr in the Mar 26 quarter, +37.4% year on year. For the full FY26 fiscal year, revenue was ₹240 Cr (+15.9%). Over the last 10 years revenue compounded at 9.5% a year. — as of 31 July 2026.
What is Chemcon Speciality Chemicals Ltd's profit?
Chemcon Speciality Chemicals Ltd earned ₹6.4 Cr of net profit in the Mar 26 quarter, +61.3% year on year. Full-year FY26 profit was ₹24.0 Cr. The operating margin ran 11.8% in the latest quarter. — as of 31 July 2026.
What is Chemcon Speciality Chemicals Ltd's market cap?
Chemcon Speciality Chemicals Ltd's market capitalisation is ₹643 Cr at a share price of ₹176. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Chemcon Speciality Chemicals Ltd's P/E ratio?
Chemcon Speciality Chemicals Ltd trades at a P/E of 27.2×, at the 39th percentile of its own 6-year range, against a long-run median of 28.7×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Chemcon Speciality Chemicals Ltd pay a dividend?
Yes — Chemcon Speciality Chemicals Ltd's dividend payout was 101% of profit in FY26, and it recorded a payout in 2 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Chemcon Speciality Chemicals Ltd overvalued?
On its own history, Chemcon Speciality Chemicals Ltd looks mid-range against its own history: its P/E of 27.2× sits at the 39th percentile of its 6-year range (long-run median 28.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Chemcon Speciality Chemicals Ltd growing?
Yes — Chemcon Speciality Chemicals Ltd is growing: latest-quarter revenue +37.4% year on year, profit +61.3%, and the margin +1.2 pp at 11.8%. The 10-year compound rates are 9.5% (revenue) and 23.1% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Chemcon Speciality Chemicals Ltd performing?
Chemcon Speciality Chemicals Ltd is in a downtrend, 32 weeks in. Its latest quarter's revenue rose 37.4% and profit rose 61.3% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Chemcon Speciality Chemicals Ltd in?
Improving — profit growth bottomed 8 quarters ago at −60.9% and has held its recovery at +61.3% (single-quarter readings), ROCE slipping at 6.0%. The read comes from the last 12 quarters of growth (revenue growth +37.4% latest, profit growth +61.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Chemcon Speciality Chemicals Ltd in an uptrend?
No — the price is in a downtrend (week 32 of stage 4), trading −6.3% versus its 200-day average and at 31% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Chemcon Speciality Chemicals Ltd beating the market?
Not lately — on a trailing-13-week view Chemcon Speciality Chemicals Ltd is currently behind the NIFTY 500 (3 weeks and counting; last ahead the week of 2026-07-10), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.8 years the stock moved −70% against the NIFTY 500's +143% — behind the index over the full window. — as of 31 July 2026.
Will Chemcon Speciality Chemicals Ltd's share price go up?
This page publishes no price forecast for Chemcon Speciality Chemicals Ltd. What it measures instead: the share price is ₹176, the price is in a downtrend 32 weeks in. Its P/E of 27.2× sits at the 39th percentile of its own 6-year range. — as of 31 July 2026.
Who owns Chemcon Speciality Chemicals Ltd?
Promoters hold 74.5% of Chemcon Speciality Chemicals Ltd, foreign institutions 0.3%, domestic institutions 0.0% and the public 25.3% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Chemcon Speciality Chemicals Ltd have too much debt?
No — Chemcon Speciality Chemicals Ltd's debt-to-equity is 0.11, and operating profit covers the interest bill 15×. FY26 borrowings were ₹53.0 Cr against equity of ₹484 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Chemcon Speciality Chemicals Ltd's capex?
Chemcon Speciality Chemicals Ltd spent ₹94.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹39.0 Cr, with ₹21.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Chemcon Speciality Chemicals Ltd's cash flow?
Chemcon Speciality Chemicals Ltd generated ₹42.0 Cr of operating cash flow in FY26 and ₹3.0 Cr of free cash flow after ₹39.0 Cr of capital spending. Reported profit that year was ₹24.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Chemcon Speciality Chemicals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 142% of Chemcon Speciality Chemicals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹42.0 Cr against reported profit of ₹24.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Chemcon Speciality Chemicals Ltd in its business cycle?
Chemcon Speciality Chemicals Ltd's FY26 operating margin was 13.0%, against a 13-year band of 10.0%–33.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 11.8%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Chemcon Speciality Chemicals Ltd story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Chemcon Speciality Chemicals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Chemcon Speciality Chemicals Ltd's earnings have outrun its stock. EPS grew −3.4% in a year against a −24.4% price move. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.